Prostate Cancer News and Research

Latest Prostate Cancer News and Research

USPTO to allow patent for Advaxis’s new vaccine technology

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has been notified that the US Patent and Trademark Office (USPTO) will allow a patent issuance of its application No. 11/785,249 entitled "Antibiotic Resistance Free Vaccines and Methods for Constructing and Using Same."

21 Aug 2010

Education and caution needed before taking nutritional supplements to reduce cancer risks

Men and women should educate themselves and use caution before taking nutritional supplements to reduce their cancer risks, according to experts at UT MD Anderson Cancer Center.

20 Aug 2010

Research finds increased diagnostic activity among men with family history of prostate cancer

The brothers of men with prostate cancer are at an increased risk of prostate cancer diagnosis because of increased diagnostic activity and not necessarily because they carry a genetic mutation that increases risk of the disease, according to a study published online August 19 in The Journal of the National Cancer Institute.

20 Aug 2010

Us TOO International Prostate Cancer Education & Support Network recognized for 20 years of service

The prostate cancer community joins together in congratulating Us TOO International Prostate Cancer Education & Support Network in their 20th anniversary of continued prostate cancer support, education and advocacy.

19 Aug 2010

Siemens Healthcare to distribute Calypso GPS System in Europe

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced that it has entered into a non-exclusive product distribution agreement with Siemens Healthcare for the sale of its Calypso® System in Europe. Under terms of the agreement, Siemens retains non-exclusive rights to sell Calypso's real-time tracking technology to existing and prospective Siemens linear accelerator customers throughout Europe for a period of three years.

19 Aug 2010

Researchers participate in Alzheimer's Breakthrough Ride to urge Congress make the disease a national priority

This summer, more than 55 researchers participating in the Alzheimer's Breakthrough Ride are cycling relay-style across the country, collecting petition signatures asking Congress to make Alzheimer's disease a national priority. The public response to the petition has been so overwhelming that as the Alzheimer's Breakthrough Riders hit the halfway point in their 67-day route from San Francisco to Washington, D.C. on August 18, they are already more than 80% of the way to their goal of 50,000 signatures.

18 Aug 2010

Loyola University Medical Center to offer free prostate cancer screenings

More than 55 million American men are at risk for developing prostate cancer, according to the American Cancer Society. This year more than 27,000 men are expected to die of the disease, which is the second-leading cause of cancer death in men.

18 Aug 2010

Robotic prostatectomy has low complication rates: CINJ study

According to a new study by The Cancer Institute of New Jersey (CINJ), new evidence proves the safety of a robotic prostatectomy with the lowest complication rates in prostate cancer treatment. This comes as no surprise to Dr. David Samadi, Chief of the Division of Robotics and Minimally Invasive Surgery in the Department of Urology at The Mount Sinai Medical Center in New York, who has performed over 3,000 successful robotic prostate surgeries in the fight against prostate cancer.

18 Aug 2010

Chronix Biomedical expands biomarker development capabilities with installation of DNA mass sequencer

Chronix Biomedical today reported that it has significantly expanded and accelerated its biomarker development capabilities with the installation of Germany's first state-of-the-art high-throughput DNA mass sequencer at the University of Göttingen, Chronix's long-time collaborator. Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

17 Aug 2010

New T cell engineering approach can improve success rate of immune-cell therapies

Clinical trials using patients' own immune cells to target tumors have yielded promising results. However, this approach usually works only if the patients also receive large doses of drugs designed to help immune cells multiply rapidly, and those drugs have life-threatening side effects. Now a team of MIT engineers has devised a way to deliver the necessary drugs by smuggling them on the backs of the cells sent in to fight the tumor. That way, the drugs reach only their intended targets, greatly reducing the risk to the patient.

16 Aug 2010

Daily dose of aspirin may reduce prostate cancer risk: US Study

A US study has found that a daily dose of aspirin may reduce the risk of prostate cancer, but Cancer Research UK has noted that regular use of aspirin can cause serious side-effects and should not be undertaken unless recommended by a doctor.Several previous studies have looked at the possibility of an association between aspirin use and a reduced risk of prostate cancer.In the latest study, scientists at the Fred Hutchinson Cancer Research Centre in Seattle, led by Dr Janet Stanford, looked at data on 1,001 prostate cancer patients and a similar number of cancer-free volunteers.

16 Aug 2010

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2010.

13 Aug 2010

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.

13 Aug 2010

Problems with analytical study design and data misinterpretation leads to biomarker failure: Report

The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article published online August 12 in The Journal of the National Cancer Institute.

13 Aug 2010

K-State researcher receives grant from NIH to continue cancer research

Understanding how cancer cells communicate with each other and how to enhance their receptiveness to drug treatments is the focus of promising work by a Kansas State University researcher.Annelise Nguyen, assistant professor of toxicology in the department of diagnostic medicine and pathobiology at K-State's College of Veterinary Medicine, recently received a $370,000 grant from the National Institutes of Health to continue her cancer research.

12 Aug 2010

Augmenix announces commercial implantation of SpaceOAR absorbable spacer system for radiation treatment

Augmenix, Inc. announced today that Prof. Michael Eble and Dr. Michael Pinkawa of the Aachen University Hospital, Aachen, Germany, performed a commercial implantation of the company's CE Mark approved SpaceOAR System. The SpaceOAR hydrogel (from spacing Organs At Risk) is designed to be a tissue compatible, absorbable spacer to reduce radiation injury to healthy tissues.

12 Aug 2010

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today released financial results for the second quarter 2010, ended June 30, 2010.

11 Aug 2010

Study examines link between breath, cancer detection

A test using a patient's breath could be developed to detect lung, breast, bowel and prostate cancers, a team of scientists have discovered. While these results are only preliminary, the study1 published in the British Journal of Cancer today (Wednesday), found that sensors could distinguish between the breath of healthy patients and those who have cancer.

11 Aug 2010

GenSpera issued additional patent for G-202

GenSpera, Inc. announced that its patent application, entitled "Tissue Specific Prodrugs," has been issued by the United States Patent and Trademark Office as US Patent 7,767,648. The patent covers the method of use for G-202, GenSpera's lead oncology drug, which is currently in a Phase I clinical study treating cancer patients whose disease has progressed after other treatments.

11 Aug 2010

Magnetic resonance image analysis helps assessment of prostate cancer severity

Rutgers researchers are developing methods that can accurately assess the severity of prostate cancer by analyzing magnetic resonance images and spectra of a patient's prostate gland. This may help physicians decide more confidently which patients need aggressive treatment and which are better served by "watchful waiting," and could even postpone or eliminate invasive biopsies in patients with low-grade tumors.

11 Aug 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

USPTO to allow patent for Advaxis’s new vaccine technology

Education and caution needed before taking nutritional supplements to reduce cancer risks

Research finds increased diagnostic activity among men with family history of prostate cancer

Us TOO International Prostate Cancer Education & Support Network recognized for 20 years of service

Siemens Healthcare to distribute Calypso GPS System in Europe

Researchers participate in Alzheimer's Breakthrough Ride to urge Congress make the disease a national priority

Loyola University Medical Center to offer free prostate cancer screenings

Robotic prostatectomy has low complication rates: CINJ study

Chronix Biomedical expands biomarker development capabilities with installation of DNA mass sequencer

New T cell engineering approach can improve success rate of immune-cell therapies

Daily dose of aspirin may reduce prostate cancer risk: US Study

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Problems with analytical study design and data misinterpretation leads to biomarker failure: Report

K-State researcher receives grant from NIH to continue cancer research

Augmenix announces commercial implantation of SpaceOAR absorbable spacer system for radiation treatment

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

Study examines link between breath, cancer detection

GenSpera issued additional patent for G-202

Magnetic resonance image analysis helps assessment of prostate cancer severity

What to know about prostate cancer eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in